Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer

被引:23
|
作者
Roe, Kathrine [1 ,2 ,3 ]
Mikalsen, Lars T. G. [4 ]
van der Kogel, Albert J. [5 ,6 ]
Bussink, Johan [5 ]
Lyng, Heidi [1 ]
Ree, Anne H. [2 ,3 ]
Marignol, Laure [7 ,8 ]
Olsen, Dag R. [9 ]
机构
[1] Oslo Univ Hosp, Inst Canc Res, Dept Radiat Biol, N-0424 Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
[3] Akershus Univ Hosp, Dept Oncol, Lorenskog, Norway
[4] Univ Oslo, Dept Phys, Oslo, Norway
[5] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, NL-6525 ED Nijmegen, Netherlands
[6] Univ Wisconsin, Dept Human Oncol, Madison, WI USA
[7] St James Hosp, Inst Mol Med, Acad Unit Clin & Mol Oncol, Prostate Mol Oncol Res Grp, Dublin 8, Ireland
[8] Univ Dublin Trinity Coll, Dublin 2, Ireland
[9] Univ Bergen, Fac Math & Nat Sci, Bergen, Norway
基金
欧盟第七框架计划;
关键词
Prostate cancer; Androgen-deprivation therapy; Radiotherapy; Immunohistochemistry; Dynamic contrast-enhanced MRI; CONTRAST-ENHANCED-MRI; VENTRAL PROSTATE; MICROVESSEL DENSITY; TUMOR XENOGRAFT; BLOOD-FLOW; HYPOXIA; RAT; EXPRESSION; CASTRATION; ANGIOGENESIS;
D O I
10.1186/1748-717X-7-75
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Radiotherapy (RT) and androgen-deprivation therapy (ADT) are standard treatments for advanced prostate cancer (PC). Tumor vascularization is recognized as an important physiological feature likely to impact on both RT and ADT response, and this study therefore aimed to characterize the vascular responses to RT and ADT in experimental PC. Methods: Using mice implanted with CWR22 PC xenografts, vascular responses to RT and ADT by castration were visualized in vivo by DCE MRI, before contrast-enhancement curves were analyzed both semi-quantitatively and by pharmacokinetic modeling. Extracted image parameters were correlated to the results from ex vivo quantitative fluorescent immunohistochemical analysis (qIHC) of tumor vascularization (9 F1), perfusion (Hoechst 33342), and hypoxia (pimonidazole), performed on tissue sections made from tumors excised directly after DCE MRI. Results: Compared to untreated (Ctrl) tumors, an improved and highly functional vascularization was detected in androgen-deprived (AD) tumors, reflected by increases in DCE MRI parameters and by increased number of vessels (VN), vessel density (VD), and vessel area fraction (VF) from qIHC. Although total hypoxic fractions (HF) did not change, estimated acute hypoxia scores (AHS) - the proportion of hypoxia staining within 50 mu m from perfusion staining - were increased in AD tumors compared to in Ctrl tumors. Five to six months after ADT renewed castration-resistant (CR) tumor growth appeared with an even further enhanced tumor vascularization. Compared to the large vascular changes induced by ADT, RT induced minor vascular changes. Correlating DCE MRI and qIHC parameters unveiled the semi-quantitative parameters area under curve (AUC) from initial time-points to strongly correlate with VD and VF, whereas estimation of vessel size (VS) by DCE MRI required pharmacokinetic modeling. HF was not correlated to any DCE MRI parameter, however, AHS may be estimated after pharmacokinetic modeling. Interestingly, such modeling also detected tumor necrosis very strongly. Conclusions: DCE MRI reliably allows non-invasive assessment of tumors' vascular function. The findings of increased tumor vascularization after ADT encourage further studies into whether these changes are beneficial for combined RT, or if treatment with anti-angiogenic therapy may be a strategy to improve the therapeutic efficacy of ADT in advanced PC. (c) 2012 Roe et al.; licensee BioMed Central Ltd.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
    Kathrine Røe
    Lars TG Mikalsen
    Albert J van der Kogel
    Johan Bussink
    Heidi Lyng
    Anne H Ree
    Laure Marignol
    Dag R Olsen
    [J]. Radiation Oncology, 7
  • [2] Timing of androgen-deprivation therapy in prostate cancer
    Del Priore, Giuseppe
    Hoffman, Steven
    [J]. LANCET ONCOLOGY, 2017, 18 (11): : E633 - E633
  • [3] Insomnia and androgen-deprivation therapy for prostate cancer
    Savard, J.
    Ivers, H.
    Simard, S.
    [J]. PSYCHO-ONCOLOGY, 2007, 16 (09) : S150 - S151
  • [4] Biopsychosocial impact of prostate cancer and androgen-deprivation therapy
    Tripp, Dean A.
    Verreault, Phylicia
    Tong, Steven
    Izard, Jason
    Black, Angela
    Siemens, D. Robert
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (10): : 338 - 343
  • [5] Complications of androgen-deprivation therapy in men with prostate cancer
    Chen A.C.
    Petrylak D.P.
    [J]. Current Urology Reports, 2005, 6 (3) : 210 - 216
  • [6] Androgen-deprivation therapy in the management of neuroendocrine prostate cancer
    Martinez-Cornelio, Andres
    Gonzalez-Perez, Juventino
    de Jesus Tabares-Garcia, Felipe
    Ramos-Salgado, Francisco
    Alvarado-Cabrero, Isabel
    Hernandez-Toriz, Narciso
    [J]. CIRUGIA Y CIRUJANOS, 2009, 77 (04): : 273 - 278
  • [7] Depression and androgen-deprivation therapy for advanced prostate cancer
    Savard, J.
    Simard, S.
    Hervouet, S.
    Ivers, H.
    Rioux, D.
    [J]. PSYCHO-ONCOLOGY, 2007, 16 (09) : S151 - S152
  • [8] Timing of androgen-deprivation therapy in prostate cancer Reply
    Duchesne, Gillian M.
    Woo, Henry H.
    [J]. LANCET ONCOLOGY, 2017, 18 (11): : E635 - E635
  • [9] COMBINED RADIOTHERAPY AND ANDROGEN-DEPRIVATION THERAPY
    不详
    [J]. CANCER DISCOVERY, 2011, 1 (03) : 197 - 197
  • [10] Depression and androgen-deprivation therapy for advanced prostate cancer
    Savard, Josee
    Simard, Sebastian
    Hervouet, Severine
    Ivers, Hans
    Rioux, Dominique
    [J]. ANNALS OF BEHAVIORAL MEDICINE, 2008, 35 : S89 - S89